Longitudinal analysis of aqueous humour cytokine expression and OCT-based imaging biomarkers in retinal vein occlusions treated with anti-vascular endothelial growth factor therapy in the IMAGINE study.
Journal
Eye (London, England)
ISSN: 1476-5454
Titre abrégé: Eye (Lond)
Pays: England
ID NLM: 8703986
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
08
11
2021
accepted:
15
09
2022
revised:
14
08
2022
pmc-release:
01
06
2024
medline:
19
6
2023
pubmed:
12
10
2022
entrez:
11
10
2022
Statut:
ppublish
Résumé
Retinal vein occlusion (RVO) is the second most common retinal vascular disorder. Despite promising advances with anti-VEGF therapy, select patients are unresponsive to therapy. A precision medicine-based approach for therapeutic decision-making based on underlying biomarkers may facilitate treatment based on the underlying pathway. This study aims to identify the baseline and longitudinal cytokine profiles of RVO-related macular oedema and correlating these expression profiles with higher order OCT features using a novel retinal segmentation and feature extraction platform. The IMAGINE study is a post-hoc assessment of aqueous humour cytokines with correlation to higher level analysis of imaging studies. OCT scans underwent machine learning enhanced segmentation of the internal limiting membrane (ILM), ellipsoid zone (EZ) and retinal pigment epithelium (RPE), as well as evaluating volumetric fluid metrics. Samples of aqueous humour were obtained at baseline, as well as months 4 and 9 prior to treatment. These samples were analysed for the expression of multiple cytokines. Patients were divided into Responders and Non-Responders based on OCT profiles. Additionally, patients were categorised as a Rebounder if their CST increased by 50% after initial improvement. Twenty-six eyes were included. The OCT-based response schema identified 21 Responders (81%) and 5 Non-Responders (19%). VEGF levels directly correlated with intraretinal fluid volume and angiogenin was inversely correlated with fluid indices. Multiple cytokines, including ANGPTL4, were directly correlated with ellipsoid zone disruption. The baseline VEGF levels were significantly higher in all responders compared to Non-Responders (p = 0.02). Rebounders tended to have significantly decreased levels of angiogenin and TIMP-1 (p = 0.019, p = 0.015). Cytokine expression was linked to specific OCT features and treatment response in RVO. Identification of an imaging phenotype that could serve as a surrogate for underlying active disease pathways could enhance treatment decision-making and precision medicine.
Sections du résumé
BACKGROUND/OBJECTIVES
OBJECTIVE
Retinal vein occlusion (RVO) is the second most common retinal vascular disorder. Despite promising advances with anti-VEGF therapy, select patients are unresponsive to therapy. A precision medicine-based approach for therapeutic decision-making based on underlying biomarkers may facilitate treatment based on the underlying pathway. This study aims to identify the baseline and longitudinal cytokine profiles of RVO-related macular oedema and correlating these expression profiles with higher order OCT features using a novel retinal segmentation and feature extraction platform.
SUBJECTS/METHODS
METHODS
The IMAGINE study is a post-hoc assessment of aqueous humour cytokines with correlation to higher level analysis of imaging studies. OCT scans underwent machine learning enhanced segmentation of the internal limiting membrane (ILM), ellipsoid zone (EZ) and retinal pigment epithelium (RPE), as well as evaluating volumetric fluid metrics. Samples of aqueous humour were obtained at baseline, as well as months 4 and 9 prior to treatment. These samples were analysed for the expression of multiple cytokines. Patients were divided into Responders and Non-Responders based on OCT profiles. Additionally, patients were categorised as a Rebounder if their CST increased by 50% after initial improvement.
RESULTS
RESULTS
Twenty-six eyes were included. The OCT-based response schema identified 21 Responders (81%) and 5 Non-Responders (19%). VEGF levels directly correlated with intraretinal fluid volume and angiogenin was inversely correlated with fluid indices. Multiple cytokines, including ANGPTL4, were directly correlated with ellipsoid zone disruption. The baseline VEGF levels were significantly higher in all responders compared to Non-Responders (p = 0.02). Rebounders tended to have significantly decreased levels of angiogenin and TIMP-1 (p = 0.019, p = 0.015).
CONCLUSIONS
CONCLUSIONS
Cytokine expression was linked to specific OCT features and treatment response in RVO. Identification of an imaging phenotype that could serve as a surrogate for underlying active disease pathways could enhance treatment decision-making and precision medicine.
Identifiants
pubmed: 36220884
doi: 10.1038/s41433-022-02265-2
pii: 10.1038/s41433-022-02265-2
pmc: PMC10275974
doi:
Substances chimiques
Endothelial Growth Factors
0
Cytokines
0
Vascular Endothelial Growth Factor A
0
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1928-1935Subventions
Organisme : NEI NIH HHS
ID : K23 EY022947
Pays : United States
Informations de copyright
© 2022. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.
Références
Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4297-302
pubmed: 18539932
Am J Ophthalmol. 2021 Feb;222:328-339
pubmed: 32896498
Invest Ophthalmol Vis Sci. 2009 Mar;50(3):1025-32
pubmed: 19060280
Indian J Ophthalmol. 2018 Sep;66(9):1291-1294
pubmed: 30127143
Trans Am Acad Ophthalmol Otolaryngol. 1974 Mar-Apr;78(2):OP166-77
pubmed: 4825042
Am J Pathol. 2013 Sep;183(3):987-95
pubmed: 23831329
Retin Cases Brief Rep. 2021 Mar 1;15(2):127-130
pubmed: 30664079
Br J Ophthalmol. 2012 Feb;96(2):302-4
pubmed: 20860986
Br J Ophthalmol. 2017 Feb;101(2):180-185
pubmed: 27073207
Doc Ophthalmol. 1999;97(3-4):217-28
pubmed: 10896335
Ophthalmology. 2012 Apr;119(4):802-9
pubmed: 22301066
Surv Ophthalmol. 2011 Jul-Aug;56(4):281-99
pubmed: 21601903
Arch Ophthalmol. 2009 Sep;127(9):1115-28
pubmed: 19752420
Ophthalmol Retina. 2021 Dec;5(12):1204-1213
pubmed: 33640493
Transl Vis Sci Technol. 2021 Mar 1;10(3):29
pubmed: 34003963
Mol Vis. 2019 Nov 15;25:756-765
pubmed: 31814701
Ophthalmology. 2017 Jun;124(6):919-921
pubmed: 28318636
Trans Am Ophthalmol Soc. 2000;98:133-41; discussion 141-3
pubmed: 11190017
Microvasc Res. 2011 Jul;82(1):1-5
pubmed: 21539846
Br J Ophthalmol. 2015 Oct;99(10):1334-40
pubmed: 25841235
Am J Ophthalmol. 2016 Aug;168:13-23
pubmed: 27130369
PLoS One. 2018 May 9;13(5):e0197322
pubmed: 29742163
J Ocul Pharmacol Ther. 2019 Sep;35(7):407-412
pubmed: 31373873
Jpn J Ophthalmol. 2011 May;55(3):256-263
pubmed: 21538000
Invest Ophthalmol Vis Sci. 2015 Jan 29;56(2):1122-8
pubmed: 25634982
J Clin Invest. 1998 Mar 15;101(6):1478-87
pubmed: 9502791
Clin Exp Ophthalmol. 2009 Jul;37(5):490-5
pubmed: 19624346
Ophthalmol Retina. 2019 Dec;3(12):1056-1066
pubmed: 31473172
Front Mol Biosci. 2016 Oct 13;3:67
pubmed: 27790618
Am J Ophthalmol. 2005 Aug;140(2):256-61
pubmed: 16086947
Ophthalmologica. 2010;224 Suppl 1:8-15
pubmed: 20714176
Br J Ophthalmol. 2016 Mar;100(3):295-9
pubmed: 26201354
Ophthalmology. 2014 Sep;121(9):1783-9
pubmed: 24768239
Ophthalmologica. 2011;225(3):150-4
pubmed: 21150231
JAMA Ophthalmol. 2013 Feb;131(2):160-5
pubmed: 23411880
Ophthalmology. 2012 Oct;119(10):2108-18
pubmed: 22817833
Ophthalmol Retina. 2019 Jan;3(1):83-92
pubmed: 30929820
Arch Ophthalmol. 1996 Oct;114(10):1243-7
pubmed: 8859084
Ophthalmology. 2010 Jun;117(6):1102-1112.e1
pubmed: 20398941
Ophthalmology. 2009 Jan;116(1):87-93
pubmed: 19118700
N Engl J Med. 1994 Dec 1;331(22):1480-7
pubmed: 7526212
Eye (Lond). 2008 Jan;22(1):42-8
pubmed: 16826241
Ophthalmic Res. 2018 May 25;:1-8
pubmed: 29804112